Quyyumi A A, Crake T, Wright C M, Mockus L J, Fox K M
Br Heart J. 1987 Jun;57(6):505-11. doi: 10.1136/hrt.57.6.505.
The role of medical treatment of patients who had resting nocturnal angina as well as exertional angina was investigate. The effects of atenolol 100 mg a day, nifedipine 20 mg three times a day, and isosorbide mononitrate 40 mg twice a day were investigated in a double blind, triple dummy randomised study. Nine patients with coronary artery disease, early positive exercise tests, and transient daytime and nocturnal ambulatory ST segment changes were initially assessed off all antianginal medication. They were then treated with each drug for three five day periods. Angina diaries were reviewed and maximal treadmill exercise tests and 48 hour ambulatory ST segment monitoring were performed at the end of each treatment period. Resting and exercise heart rate and blood pressure were significantly lower on atenolol than on either isosorbide mononitrate or nifedipine. The duration of exercise to 1 mm ST segment depression was significantly greater on atenolol than on isosorbide mononitrate. Only one patient had an improvement in exercise tolerance on nifedipine that was greater than the improvement on atenolol; this patient had single vessel disease. The total number and duration of episodes of ST segment change during ambulatory monitoring were significantly lower with atenolol than on either isosorbide mononitrate or nifedipine. Nocturnal ST segment changes were abolished in six patients on atenolol, in six patients on nifedipine, and in five patients on isosorbide mononitrate. When nocturnal ST segment changes occurred, their frequency was reduced with all three drugs. Pain was abolished in four patients on atenolol and pain relief was significantly better on atenolol than on isosorbide mononitrate. There was no significant difference in pain relief between isosorbide mononitrate and nifedipine. Thus beta receptor blockade with atenolol was the most effective means of reducing myocardial ischaemia both during exercise and at rest at night without causing deterioration in any patient. Nocturnal myocardial ischaemia in patients with severe coronary artery disease can be effectively treated with beta receptor antagonists and vasodilators.
对患有静息性夜间心绞痛以及劳力性心绞痛患者的药物治疗作用进行了研究。在一项双盲、三模拟随机研究中,考察了每日服用100毫克阿替洛尔、每日三次服用20毫克硝苯地平以及每日两次服用40毫克单硝酸异山梨酯的效果。9名患有冠状动脉疾病、运动试验早期阳性以及日间和夜间动态ST段短暂改变的患者,最初在停用所有抗心绞痛药物的情况下进行评估。然后,他们分别接受每种药物治疗三个为期五天的疗程。在每个治疗疗程结束时,查阅心绞痛日记,并进行最大运动平板试验和48小时动态ST段监测。服用阿替洛尔时的静息和运动心率及血压显著低于服用单硝酸异山梨酯或硝苯地平。与单硝酸异山梨酯相比,服用阿替洛尔时运动至ST段压低1毫米的持续时间显著更长。只有1名单支血管病变的患者服用硝苯地平后运动耐量的改善大于服用阿替洛尔后的改善。动态监测期间ST段改变发作的总数和持续时间,服用阿替洛尔时显著低于服用单硝酸异山梨酯或硝苯地平。6名服用阿替洛尔的患者、6名服用硝苯地平的患者和5名服用单硝酸异山梨酯的患者夜间ST段改变消失。当出现夜间ST段改变时,三种药物均可降低其发作频率。4名服用阿替洛尔的患者疼痛消失,且阿替洛尔的止痛效果显著优于单硝酸异山梨酯。单硝酸异山梨酯和硝苯地平之间的止痛效果无显著差异。因此,阿替洛尔进行β受体阻滞是在运动期间和夜间休息时减少心肌缺血的最有效方法,且不会导致任何患者病情恶化。重度冠状动脉疾病患者的夜间心肌缺血可用β受体拮抗剂和血管扩张剂有效治疗。